Bind declines on mixed lung cancer results
This article was originally published in Scrip
Executive Summary
Bind Therapeutics saw its stock price fall 20.4% to $8.40 per share on 19 November after results from the company's first-ever clinical trial showed low response rates and survival for lead drug candidate BIND-014 in non-small cell lung cancer (NSCLC) with slightly higher responses and longer survival in certain hard-to-treat populations.